CRNKL1

Across TCGA pan-cancer cohorts, CRNKL1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CRNKL1 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CRNKL1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CRNKL1 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

GBM, PDAC, and LSCC are the cancer types where CRNKL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.540	0.282	.002	10	view →
PDAC	OS	Quartile	II,III,IV	0.729	1.000	.002	9	view →
LSCC	DFS	Median	II,III,IV	0.824	0.556	.009	6	view →
HNSC	OS	Median	All	1.000	0.960	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CRNKL1–GBM (OS)

Open the GBM breakdown →